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Plasmodium falciparum 19-Kilodalton Merozoite Surface Protein 1
(MSP1)-Specific Antibodies That Interfere with Parasite Growth
In Vitro Can Inhibit MSP1 Processing, Merozoite Invasion,
and Intracellular Parasite Development
David K. Moss,a Edmond J. Remarque,b Bart W. Faber,b David R. Cavanagh,c David E. Arnot,c
Alan W. Thomas,b and Anthony A. Holdera
Division of Parasitology, MRC National Institute for Medical Research, Mill Hill, London, United Kingdoma; Department of Parasitology, Biomedical Primate Research
Centre, Rijswijk, The Netherlandsb; and Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, United Kingdomc
Merozoite surface protein 1 (MSP1) is a target for malaria vaccine development. Antibodies to the 19-kDa carboxy-terminal re-
gion referred to as MSP119 inhibit erythrocyte invasion and parasite growth, with someMSP1-specific antibodies shown to in-
hibit the proteolytic processing of MSP1 that occurs at invasion.We investigated a series of antibodies purified from rabbits im-
munized withMSP119 and AMA1 recombinant proteins for their ability to inhibit parasite growth, initially looking at MSP1
processing. Although significant inhibition of processing was mediated by several of the antibody samples, there was no clear
relationship with overall growth inhibition by the same antibodies. However, no antibody samples inhibited processing but not
invasion, suggesting that inhibition of MSP1 processing contributes to but is not the only mechanism of antibody-mediated in-
hibition of invasion and growth. Examining other mechanisms by whichMSP1-specific antibodies inhibit parasite growth, we
show that MSP119-specific antibodies are taken up into invaded erythrocytes, where they persist for significant periods and re-
sult in delayed intracellular parasite development. This delay may result from antibody interference with coalescence of MSP119-
containing vesicles with the food vacuole. Antibodies raised against a modified recombinant MSP119 sequence were more effi-
cient at delaying intracellular growth than those to the wild-type protein. We propose that antibodies specific for MSP119 can
mediate inhibition of parasite growth by at least three mechanisms: inhibition of MSP1 processing, direct inhibition of invasion,
and inhibition of parasite development following invasion. The balance betweenmechanismsmay be modulated by modifying
the immunogen used to induce the antibodies.
Malaria remains a major disease in Africa, Asia, and LatinAmerica with an estimated 300 to 500 million cases and up
to a million deaths per year (41). To date, no registered vaccine has
been developed, and artemisinin combination therapies (ACTs)
are currently the main treatment for clinical disease due to infec-
tions with Plasmodium falciparum, the principal human patho-
gen. There is an ever-present risk of parasites developing drug
resistance and thus a clear public health need to develop an effec-
tive vaccine. RTS,S, a vaccine based on the circumsporozoite sur-
face protein, is currently undergoing phase III trials, but there is
still a major interest to develop a vaccine that includes a compo-
nent(s) directed at the asexual blood stage (22). Two P. falciparum
proteins that have been researched extensively as vaccine targets
are merozoite surface protein 1 (MSP1) and apical merozoite an-
tigen 1 (AMA1), but there is still uncertainty about how a protec-
tive immune response against these targets may act. Recent vac-
cine trials with these antigens have produced disappointing results
(31, 37), suggesting that we need to understand better the mech-
anisms of immunity and potentially engineer the antigens to im-
prove the responses (21).
MSP1 is the most characterized merozoite surface protein (21)
and is essential during the invasive blood stage (11). It is synthe-
sized in schizonts as an190-kDa protein, which is cleaved by P.
falciparum subtilisin 1 (PfSUB1) at the end of schizogony into four
polypeptides of characteristic length: p83, p42, p38, and p30 (9).
These fragments remain associated together on the parasite’s sur-
face via noncovalent bonds, along with several other surface pro-
teins (33, 38), and anchored to the plasma membrane via the
C-terminal glycosylphosphatidylinositol (GPI) moiety located on
the 42-kDa fragment (MSP142) (17). MSP1 may play a role in the
initial binding of the merozoite to an erythrocyte (34). During the
final stages of erythrocyte invasion, MSP142 undergoes a second
cleavage event called secondary processing and mediated by an-
other parasite subtilisin (PfSUB2 [20]), generating MSP133 and
MSP119. The result of this cleavage is the shedding of the majority
of the MSP1 and its associated protein complex, a process that has
been linked with loss of the merozoite coat during erythrocyte
invasion (6). However, MSP119 remains attached to the merozoite
due to the GPI anchor and is taken into the erythrocyte (5, 7, 13).
The role MSP119 plays in subsequent intracellular parasite devel-
opment is unclear, although it is the first known marker for the
developing food vacuole where it persists until the end of the in-
tracellular cycle and is discarded in the residual body together with
products of digestion such as hemozoin (13). There is abundant
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evidence that antibodies to MSP119 can interfere with parasite
growth, and a range of mechanisms have been proposed, ranging
from steric inhibition of parasite binding to erythrocytes and in-
hibition of SUB2-mediated secondary processing to the recruit-
ment of cellular functions through Fc-mediated mechanisms (2,
7, 18, 19, 27, 30).
The structure of P. falciparum MSP119 has been elucidated and
used to define the epitopes recognized by monoclonal antibodies
(MAbs) that when bound inhibit secondary processing (28, 29,
35). In addition, the modification of MSP119 by substitution of
different amino acid residues has been helpful not only to identify
the epitopes of these classes of antibody, but also to define a third
class of antibody (called blocking antibodies) that competes with
inhibitory antibodies and therefore allows secondary processing
to proceed even in the presence of the inhibitory antibodies (19,
39). Some of these modified MSP119 antigens have been proposed
to offer advantages over the wild-type antigen in that they might
induce fewer blocking antibodies when used as an immunogen
(21, 23, 39).
AMA1 reaches the merozoite surface from the microneme or-
ganelles. Although its role in invasion is different from that of
MSP1, it is also shed from the merozoite surface by the action of
SUB2 (24). Antibodies to AMA1 have been shown to be highly
effective at reducing parasite invasion in vitro and also to interfere
with AMA1 processing (14, 15).
In a search for the antigens to include in an asexual blood-stage
vaccine, a number of MSP1 constructs have been compared (1,
36). This comparison has included proteins produced via different
expression systems, modified forms of MSP1 to include amino
acid substitutions, and chimeric proteins consisting of fused
AMA1 and MSP1 sequences (1, 16). In this work, we used reagents
previously developed to some of these antigens (1) to further clar-
ify the importance and mechanism by which MSP119 antibodies
can inhibit parasite growth and development. We show that al-
though MSP1 processing by SUB2 is inhibited by some of the IgGs
tested, this activity alone cannot account for the observed inhibi-
tion of growth. However, in no instance was a high inhibition of
MSP1 processing associated with a low inhibition of growth, sug-
gesting that SUB2 processing of MSP1 is a key prerequisite for
erythrocyte invasion. We provide evidence that MSP119-specific
IgG is taken up along with the invading merozoite into an eryth-
rocyte and that these antibodies can delay the intracellular devel-
opment of the parasite, possibly by interfering with the formation
of the food vacuole. Based on these observations, we propose a
model in which MSP119-specific IgGs can inhibit parasite growth
by at least three mechanisms: inhibition of MSP1 secondary pro-
cessing, direct inhibition of invasion, and inhibition of an MSP1
function that is important postinvasion, for example at its loca-
tion in the food vacuole. These results suggest that a modified
protein is more effective than the wild-type recombinant protein
in inducing antibodies that delay intracellular development.
MATERIALS AND METHODS
IgG production. The antibodies raised against a variety of recombinant
MSP119 and AMA1 proteins used in this study were purified from serum
produced as part of the EUROMALVAC II Integrated Project (1). Groups
of individual rabbits were immunized with one of six antigen prepara-
tions: AMA1, a mixture of AMA1 and wild-type MSP119 (mix), an AMA1-
MSP119 fusion protein (fusion) (16), wild-type MSP119 expressed in
Pichia pastoris (MSP1wt), wild-type MSP119 expressed from recombinant
baculovirus in insect cells (MSP1bac; kindly provided by Shirley Longa-
cre, Institut Pasteur), and mutant MSP119 expressed in Pichia pastoris
(MSP1mut; Cys12 and Cys28 replaced by Ile and Trp, respectively); fur-
ther details of antigens have been described previously (1). All IgGs used
in these studies were purified from individual serum samples by affinity
chromatography on protein G columns. Total IgG concentration was
measured by spectroscopy.
MSP1 and AMA1 processing assay. Each of the IgG fractions pro-
duced was tested for its ability to block secondary processing of MSP1,
using a modified processing assay and merozoites (4). In brief, merozoites
(3D7 line) were harvested in a medium containing EGTA to chelate Ca2
and prevent SUB2 activation and then stored at 80°C. Prior to use,
merozoites were thawed on ice, washed, and then resuspended in 10 mM
Tris-HCl buffer (pH 8.0). To aliquots of merozoites, IgG samples were
added to a final concentration of 5 mg ml1 and SUB2 was activated by the
addition of CaCl2 to 5 mM (final). Samples were incubated for 15 min at
37°C before centrifugation and supernatant collection. Processing was
determined by SDS-PAGE and Western blotting to detect shed products:
MSP133 using the specific antibody X509 (8), and the 44-kDa fragment of
AMA1 using the 4G2 antibody (10). Following chemiluminescence and
fluorography, signals were analyzed using ImageJ software to determine
relative band intensities and calculate the percentage of processing in the
presence of each IgG, compared to controls using the following equation:
percentage processing  100  [(IgG Int  negative control Int)/(posi-
tive control Int negative control Int)], where Int is band intensity. The
positive control sample contained neither IgG nor EGTA, and the nega-
tive control contained an excess of EGTA to suppress further process-
ing (6).
Growth and manipulation of P. falciparum cultures. P. falciparum
3D7 parasites were routinely cultured at 2% hematocrit and 37°C in RPMI
1640 medium containing Albumax (Gibco 041-91762A) and glutamine.
Merozoites were collected as described previously (4). For the inhibition
of growth assays, parasites were first partially synchronized using mag-
netic collection of schizonts. Two hours postinvasion, the cells were pel-
leted by centrifugation and then suspended in a final concentration of 5%
sorbitol at 37°C for 10 min to remove any remaining schizonts. Following
sorbitol treatment, the cells were pelleted again and washed twice in fresh
medium prior to resuspension in medium at 1% parasitemia and 2%
hematocrit for further culture. Synchronized cultures were grown for ap-
proximately 40 h or until the next schizogony.
Growth assay by FACS analysis of hydroethidine (HE)-stained par-
asites and by microscopy of Giemsa-stained smears. Assays to examine
the effect of antibodies on parasite growth were carried out in a 96-well
plate format, with a final volume of 100l for each culture (75l of stock
culture plus 25 l of a 20 mg ml1 IgG stock). Each assay was performed
in duplicate. Following setup, plates were incubated in a humid chamber
containing 90% nitrogen, 5% carbon dioxide, and 5% oxygen at 37°C.
After one cycle of invasion to the next schizont stage (typically 44 to 48 h),
the samples were analyzed by fluorescence-activated cell sorter (FACS)
(3). In brief, 50l of sample was added to 500l of freshly diluted hydro-
ethidine fluorescence stain (HE; 17084; Polysciences Inc.; 1:200 dilution
of 10 mg ml1 stock in 100% dimethyl sulfoxide [DMSO]) and incubated
for 20 min at 37°C. Samples were then diluted with 1 ml of phosphate-
buffered saline (PBS) to enable appropriate FACS counting. Staining was
stopped by storing the samples on ice in the dark. For negative controls,
noninfected red blood cells were HE stained and processed in the
same way.
Parasitemia was calculated using the FACSCalibur flow cytometer
(Becton Dickson). In brief, cells to be counted were initially screened
using forward and side scatter parameters and gated for erythrocytes.
From this gated population, the HE staining was determined using the
FL2 detector (585/42 nm) with 50,000 cells counted. When expressed as a
histogram of HE intensity versus cell number, a distinct population rep-
resenting trophozoite/schizont-infected erythrocytes is evident and can
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be used to calculate the parasitemia as follows: growth inhibition 100
(100 average parasitemia in the presence of IgG/control parasitemia).
To confirm the stage of parasites within the asexual cycle, thin smears
were prepared, methanol fixed, stained with Giemsa’s reagent, and exam-
ined by microscopy. The parasites were divided into three classes: ring
stage (early trophozoite), late trophozoite (hemozoin clearly evident, sin-
gle nucleus), and schizont (multiple nuclei with or without segmenta-
tion).
IgG uptake assay. Parasite cultures were set up as described above for
FACS analysis, and IgG was added to each well at a final concentration of
0.5 mg ml1 (a non-invasion-inhibitory concentration). Parasites were
allowed to invade and then following invasion (determined by the pres-
ence of early-ring-stage parasites in control cultures), plates were briefly
centrifuged to pellet cells. The cells were then washed with fresh medium
(3 100l), resuspended to 100l, and incubated for various periods in
the gassed humid chamber. To examine for the presence of IgG that had
been taken up at various time points, smears were prepared, dried, and
stored (20°C) for subsequent immunolabeling. The smears were fixed
in 4% formaldehyde-PBS for 15 min, extracted with 1% Triton X-100
(vol/vol) in PBS for 5 min, and then blocked in 3% bovine serum albumin
(BSA) (wt/vol) in PBS for 60 min. Antibodies were detected by the addi-
tion of Alexa Fluor488-tagged goat anti-rabbit IgG (A11034; Molecular
Probes) and mounted in ProLong Gold containing DAPI (4=,6-di-
amidino-2-phenylindole; P771644; Invitrogen). Slides were examined us-
ing a Zeiss Axiovert 200 microscope using a 100 objective, and images
were acquired using Axiovision 4.0 software (Zeiss), with additional pro-
cessing using Adobe Photoshop.
RESULTS
MSP142 processing assay. The initial aim of this study was to
determine whether antibodies raised by immunization with a va-
riety of recombinant MSP119 proteins could inhibit the secondary
processing of MSP142, and if so to what extent this activity con-
tributed to their overall ability to inhibit parasite growth in vitro. A
previous study had shown that these sera contained antibodies
that inhibited parasite growth (1). Secondary processing was de-
termined by the detection of MSP133 using Western blotting and
ImageJ analysis. By comparing the amount of MSP133 produced
in the presence of antibody to that in the positive (absence of IgG)
and negative (in the presence of EGTA to inhibit SUB2 process-
ing) controls, we were able to calculate the percentage of MSP1
processing in the presence of each IgG (Fig. 1A). The assay showed
a general trend for decreased MSP1 processing when the IgG sam-
ples were grouped according to the antigen they had been raised
against, from high to low: AMA1 alone, AMA1-MSP1 mix/fusion,
MSP1wt, MSP1mut, and MSP1bac (Fig. 1B). Although the assay
was rigorously controlled at all steps through sample preparation,
minimal handling, and the inclusion of controls on each gel, a
significant variability in MSP1 processing was noted, which is re-
flected in the error bars. IgGs that were raised against antigen
containing an AMA1 component also inhibited the processing of
AMA1 (Fig. 1C). These assays were carried out at 2.5 mg ml1 to
avoid background problems. Importantly, when we grouped IgG
samples according to their antigen specificity, there was a distinct
difference in their inhibition of either AMA1 or MSP1 processing.
Although for the MSP1 assay all IgGs were used at the same
concentration, to clarify whether the observed inhibition of pro-
cessing was due to MSP1-specific IgG, we compared the MSP1
processing inhibition to its MSP1-specific titer, using enzyme-
linked immunosorbent assay (ELISA) data from reference 1 (Fig.
1D). From this analysis there was no clear relationship between
ELISA titer and percentage processing in most cases; MSP1wt and
MSP1mut gave the highest correlation (R2  0.69 and 0.56, re-
spectively). Within the MSP1bac group, all IgGs gave significant
inhibition of MSP1 processing (60%), but there was a range of
IgG titers (Fig. 1D).
Relationship between inhibition ofMSP1 processing and in-
hibition of parasite growth. The primary role of MSP1 during
invasion is believed to be in host cell recognition and attachment,
with the SUB2-mediated cleavage acting to remove the majority of
the complex, presumably after this role is completed. Accordingly,
it has been proposed that a primary mechanism by which MSP1-
specific antibodies may inhibit parasite growth is via the inhibi-
tion of secondary processing (7, 19). We therefore looked for any
correlation between the extent of antibody-mediated inhibition of
parasite growth and MSP1 secondary processing. Since our pro-
cessing assays were performed with merozoites from the 3D7 line,
we used the same parasite to carry out growth inhibition assays
using the vital stain hydroethidine (HE) and a FACS procedure
(Fig. 2A).
If inhibition of secondary processing is a principal factor in the
inhibition of parasite invasion and growth, then we would predict
a direct relationship between the inhibition of growth and the
reciprocal of the MSP1 processing (1/P) in the presence of anti-
body, i.e., the less MSP1 secondary processing the greater the in-
hibition of parasite growth. However, for none of the IgG groups
tested was a tight correlation observed (Fig. 2B, R2 values), al-
though we did note a general grouping of results based on the
antigen used to raise the antibodies. Nevertheless, in no instance
was there inhibition of MSP1 processing in the absence of growth
inhibition (Fig. 2B, top left quadrant), indicating that when the
antibodies did inhibit MSP1 processing it was contributing in
some degree to the overall inhibition of parasite growth. IgG sam-
ples produced by immunization with AMA1-based antigens all
fall in the lower half of the graph (Fig. 2B). This was expected as
each IgG contains an AMA1 antibody component capable of con-
tributing to parasite growth inhibition but which will have no
effect on the measured MSP1 processing. Of the three groups of
antibody samples raised to recombinant MSP1, those produced by
immunization with the wild-type MSP1 produced in Pichia gave
the most consistent but lowest inhibition of processing, while the
two remaining groups (MSP1bac and MSP1mut) had several IgG
samples giving significant inhibition of MSP1 processing, though
as groups these also had the widest range. Based on the titer of
MSP1-specific IgG in the samples, there was a strong direct rela-
tionship between the level of specific antibody and inhibition of
parasite growth (Fig. 2C), which was not present when the level of
specific antibody was compared to inhibition of processing
(Fig. 1D).
IgG uptake at merozoite invasion delays intracellular para-
site development. The FACS-based growth inhibition assay uses
HE as a vital stain that requires the parasite to be metabolically
active to convert the HE to ethidium, which then binds to DNA.
The amount of DNA in the cell reflects the parasite’s stage of
development: ring (early trophozoite) and trophozoite stages have
a single copy of the genome; schizogony requires extensive DNA
synthesis, replication, and nuclear division. Therefore, as the par-
asite progresses through its intracellular development more DNA
is present, and this higher DNA content results in greater incor-
poration of ethidium and higher fluorescence intensity. This is
indicated by the right shift in the histogram generated by the
FACS.
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Although the overall parasitemia was measured and used to
calculate growth inhibition mediated by the presence of specific
IgG, it was noted that for some groups there was a left shift in the
histograms, indicating the presence of earlier-stage or delayed
parasites (Fig. 3A). To confirm this observation, the growth inhi-
bition assays were repeated with a selection of IgGs and the para-
site morphology analyzed by microscopy of smears stained with
Giemsa’s reagent. Interestingly, when the parasites were treated
with antibodies raised to a recombinant protein including MSP1,
there was a noted delay in parasite development in the parasites
present compared to controls (Fig. 3A). This was particularly ev-
ident in the presence of antibodies raised to MSP1mut. For such
developmental delay and morphological changes to occur, it was
predicted that some of the antibody must be taken into the eryth-
rocyte with the invading merozoite, a feature previously observed
for the monoclonal antibodies 111.4 and 1E1, which accumulate
together with MSP119 in the food vacuole (13). To determine if
any IgG was taken into the erythrocyte, we repeated the assays
FIG 1 Analysis of MSP1 processing in the presence of specific antibody. (A) Images representative of MSP1 blots used for analysis of MSP142 processing as
estimated by ImageJ analysis of Western blot data. The intensity of the signal due to X509 binding to MSP133 was quantified by densitometry for each IgG sample
expressed as a percentage relative to positive controls. Samples are displayed according to the antigen: AMA1, mixed AMA1 and MSP119wt (mix), AMA1-MSP119
fusion (fusion), MSP119wt (MSP1wt), baculovirus-expressed MSP119wt (MSP1bac), and mutant MSP119 (MSP1mut) with the numbers identifying particular
IgG samples. The positive (P) and negative (N) controls, as well as a known processing-inhibitory monoclonal antibody (MAb 12.8), are included. Purified IgG
(5.0 mg ml1) was used, with standard deviation indicated. Student’s t test was used to determine statistical significance in relation to the positive control (P
values: *, 0.01 to 0.05; **, 0.01 to 0.001; and ***,0.001). (B) Inhibition of MSP1 processing by specific IgG antigen group. Student’s t test was used to determine
statistical significance compared to the control. (C) Inhibition of AMA1 processing estimated by ImageJ analysis of Western blot data. Pooled IgG from the
groups defined in A. IgG was added at 2.5 mg ml1, and the percentage of processing relative to positive controls was calculated. Student’s t test was used to
determine statistical significance in relation to the positive control. (D) Graph depicting MSP1 processing in the presence of the various IgG samples compared
with their MSP1 titer by ELISA.
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using a low concentration of IgG (0.5 mg ml1). Thin smears were
prepared, and the parasites were examined at 5, 15, and 35 h post-
invasion using immunofluorescence following permeabilization
of the cells and the addition of a labeled second antibody. We
identified antibody within infected erythrocytes, indicating that
some of the IgG was taken in along with the invading merozoite
and persisted until at least 35 h postinvasion (Fig. 3B). There was
no detectable uptake of AMA1-specific antibodies or IgG controls.
These results are consistent with the uptake of antibody bound
directly to MSP1 and agree with our FACS and parasite staging
data (Fig. 3A). Previous studies have reported the specific uptake
of MSP119-specific antibodies (4, 13). Although labeling was pres-
ent in the parasites incubated with all the MSP1-specific IgGs, the
intensity and duration of label were greatest for those samples
produced by immunization with MSP1wt and MSP1mut. In late-
stage parasites, the IgG was detected in the food vacuole as iden-
tified by the hemozoin crystal (Fig. 3C, 35 h) but also elsewhere
throughout the cytoplasm, presumably in vesicles that had failed
to coalesce with the food vacuole; such vesicles had been identified
previously in MSP1 uptake studies (13). In contrast, the MAb 1E1
labeling coalesced to a single location by 15 to 17 h postinvasion,
as described previously (13). These results indicate that the
MSP119-specific antibodies may delay or obstruct food vacuole
formation (Fig. 3C).
DISCUSSION
The initial aim of this work was to evaluate the contribution made
by antibodies that inhibit secondary processing of MSP1 to the
antibody-mediated inhibition of parasite growth in vitro. We used
preparations of rabbit antibodies that had been raised by immu-
nization with a range of recombinant proteins comprised of
MSP119 sequences, either alone or in combination with AMA1-
derived sequences (29). By applying tight protocols, the pooling of
merozoite sample preparations and the inclusion of reference
samples on each SDS-PAGE gel, we have been able to detect the
contribution processing inhibition makes to the mechanisms of
FIG 2 Correlation between parasite growth inhibition, inhibition of MSP1 processing, and antibody titer. (A) Analysis of the inhibition of parasite growth in the
presence of specific antibody, as determined by hydroethidine staining and FACS counting. The percentage of growth inhibition was calculated relative to
controls. Antibodies from individual sera, identified and grouped as defined for Fig. 1, were used. The data are from three representative independent
experiments; in each case, a final concentration of 5.0 mg ml1 purified IgG was used. The standard deviation is indicated; Student’s t test was used to determine
statistical significance in relation to the positive control (P values: *, 0.01 to 0.05; **, 0.01 to 0.001; and ***,0.001). (B) Comparison of the inhibition of parasite
growth and MSP142 processing by individual antibody samples from rabbits immunized with AMA1 alone (AMA1, black squares), a mixture of AMA1 and
wild-type MSP119 (mix, white squares), an AMA1-MSP119 fusion protein (fusion, gray squares), wild-type MSP119 expressed in Pichia pastoris (MSP1wt, black
circles), wild-type MSP119 expressed from recombinant baculovirus in insect cells (MSP1bac, white circles), and mutant MSP119 expressed in Pichia pastoris
(MSP1mut, gray circles). The antibodies from groups of animals immunized with MSP119 alone are ringed. The calculated R
2 values for each group of antibody
samples are listed in the table (bottom right). (C) Correlation of anti-MSP1 antibody titer as determined by ELISA (data from reference 1) with antibody-
mediated inhibition of growth as determined by FACS. The antibody samples were from animals immunized with wild-type MSP119 expressed in Pichia pastoris
(MSP1wt, black circles), wild-type MSP119 expressed from recombinant baculovirus in insect cells (MSP1bac, white circles), and mutant MSP119 expressed in
Pichia pastoris (MSP1mut, gray circles). The calculated correlation for each slope is indicated.
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overall growth inhibition by these antibodies. The specificity of
the assay was confirmed by including AMA1-specific antibodies,
which as a group showed no MSP1 processing inhibition (Fig. 1A
and B) (average 95% of control). Furthermore, the IgG inhibition
of MSP1 processing by SUB2 does not affect the SUB2 processing
of AMA1 or vice versa.
Although antibodies from these serum samples have been ex-
amined previously for their ability to inhibit parasite growth in
vitro, these studies used the Wellcome and FCR3 lines of P. falcip-
arum in a lactate dehydrogenase-based assay (1), and there is ev-
idence for varying responses between parasite lines (2, 3). As part
of this work, we retested each IgG sample in HE and FACS-based
FIG3 The effect of antibodies on intracellular parasite development. (A) Analysis of parasites40 h postinvasion by FACS following hydroethidine staining and
by microscopy following Giemsa staining. In the presence of specific antibodies, parasite development was delayed as shown by DNA fluorescence (ethidium
labeling moved to left; MSP1mut antibody-treated parasites shown) and morphology compared to control parasites; the proportions of schizonts (black),
trophozoites (gray), and early trophozoites (white) in each population are indicated in the graph. (B) MSP119-specific antibody is taken up into parasites at
invasion and persists during development. The table on the left indicates the presence of detectable antibody at 5, 15, and 35 h postinvasion for parasites incubated
with antibodies raised against the various proteins, and on the right are images of parasites from the different time points stained for the presence of rabbit IgG
(green) and with DAPI (blue) to locate the nuclei. Representative images are shown for the groups that gave the most pronounced IgG labeling, along with the
AMA1 and irrelevant IgG controls. (C) Comparison of MSP1 IgG labeling compared to control cultures containing MSP1-specific MAb 1E1 at early stages of
parasite development, 3 to 5 and 15 to 17 h postinvasion. At later time points (35 h), MSP1 IgG labeling was evident and associated with hemozoin (arrows) and
cytosolic structures (asterisks).
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growth inhibition assay (3). This system incorporates a measure of
parasite viability and gives an indication of the developmental
stage of the parasite population by DNA content as measured by
the amount of ethidium bound. From this, we show that for the
MSP1-specific IgGs there was limited correlation between IgG-
mediated inhibition of processing and growth. This correlation
was reduced even further when antibodies to AMA1 were present
(mix and fusion antigens) and was negligible for AMA1-specific
antibodies. However, none of the IgG samples gave a high inhibi-
tion of MSP1 processing but a low level of growth inhibition,
indicating that when present, inhibition of MSP1 processing con-
tributes to growth inhibition.
Although there is evidence for a correlation between the
MSP1-specific antibody titer and inhibition of growth, there was
little if any correlation between MSP1 antibody titer and inhibi-
tion of MSP1 processing. It is of note that in two of the antigen
groups (MSP1bac and MSP1mut), there were IgG samples with
low MSP1 titers but which gave significant MSP1 processing inhi-
bition (80%), a level that was comparable with that of other IgG
samples tested with significantly higher MSP1 titers by ELISA.
Thus, MSP1 processing inhibition is not merely dependant on IgG
concentration.
Together, these results indicate that antibodies that inhibit
MSP1 secondary processing are not a major component of the IgG
fraction and that IgGs act via other mechanisms to contribute to
the overall inhibition of parasite growth. However, the results do
not rule out the potential of engineering the antigen, for example
enhancing the processing inhibition activity by manipulating the
sequence of the antigen. Reducing the induction of blocking an-
tibodies that prevent the binding of processing inhibitory anti-
bodies is one strategy to achieve this (39).
Several aspects of our data show that when MSP1-specific IgG
was present, the parasites that developed were significantly de-
layed compared to controls. This is in agreement with a previous
study using the same sera that noted a change in parasite morphol-
ogy (1). Using non-growth-inhibiting concentrations of IgG, we
were able to detect MSP119-specific IgG within infected erythro-
cytes up to at least 35 h postinvasion, indicating that IgG was taken
into the parasitophorous vacuole bound to MSP119 of the invad-
ing merozoite. The presence of MSP119-specific IgGs within
erythrocytes is in agreement with a previous study using MAbs
(13) and morphological observations made using polyclonal an-
tibodies (1, 2, 40). It is known that MSP119 is carried into the
infected cell and persists postinvasion (5, 26), accumulating in
the food vacuole and finally shed within the residual body (13).
The fact that IgGs are taken in with the merozoite and remain
bound over a significant period of the parasite’s life cycle places
them in an appropriate location to inhibit intracellular develop-
ment, thus contributing to inhibition of parasite growth. We ob-
served IgG labeling around the hemozoin, indicating association
with the food vacuole as well as IgG within subcytoplasmic com-
partments, possibly the early vesicles that coalesce to form the
food vacuole (13). The extensive cytoplasmic labeling was not
evident in the MAb 1E1 control, consistent with a possible disrup-
tion or delay in food vacuole formation.
The mechanisms by which an antibody response to MSP119
contributes to protective immunity in vivo are still not fully re-
solved (30). However, antibody fine specificity (12, 32) and Fc-
mediated mechanisms (25, 27) are important. Data acquired in
this study suggest that polyclonal antibodies to MSP119 can inhibit
parasite invasion of erythrocytes by inhibiting MSP1 processing
and by a second, potentially more important mechanism, perhaps
steric hindrance of parasite binding. The fact that another factor
other than MSP1 processing is involved means that the processing
assay alone is an inadequate method to assay antibody-mediated
inhibition of parasite growth. However, since some MAbs show
good activity in both processing and invasion inhibition (7, 19,
25), it remains a viable tool to dissect the mode of action of MSP1-
specific antibodies. The contribution inhibition of intracellular
growth makes toward the protective effect of anti-MSP1 antibod-
ies needs further investigation, but it is interesting that an engi-
neered variant of MSP119 appears able to induce antibodies that
are more active in this assay than those induced by the wild-type
protein, suggesting that the fine specificity of the antibodies may
contribute to this mechanism. These results are consistent with
the notion that engineering or modifying the MSP1 antigen may
convey properties that improve its potential for vaccine develop-
ment.
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